文献速递头颈外科

治疗前循环肿瘤组织修饰病毒HPV DNA与HPV阳性口咽癌临床病理因素的关联

Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项横断面研究纳入2019年12月至2022年1月在Dana-Farber癌症研究所评估的110例HPV阳性口咽鳞状细胞癌患者,检测治疗前循环肿瘤组织修饰病毒(TTMV)HPV DNA。TTMV HPV DNA检出与临床N分期最强相关,N0期患者检出比例低于N1-N3期患者,且DNA评分随淋巴结分期、最大淋巴结直径及淋巴结最大标准化摄取值升高而增加。

要点

  • 110例患者中98例(89%)可检出循环TTMV HPV DNA,中位评分315片段/mL。
  • 临床N0期患者仅4/11(36%)可检出DNA,低于N1-N3期的94/99(95%)。
  • TTMV HPV DNA检出率与评分随临床淋巴结分期、最大淋巴结直径及淋巴结最大标准化摄取值升高而增加。

核心结论

  • 在HPV阳性口咽鳞状细胞癌诊断时,循环TTMV HPV DNA与淋巴结病变呈统计学显著关联。
  • 少数不可检出患者的临床分期以N0期为主,提示无颈部淋巴结肿大患者的检测敏感性可能较低。
  • 该关联的机制及该生物标志物用于基线不可检出患者监测的价值有待进一步研究。

研究设计与样本

  • 横断面研究,纳入2019年12月至2022年1月在马萨诸塞州波士顿Dana-Farber癌症研究所评估并接受根治性治疗的HPV阳性口咽鳞状细胞癌患者110例。
  • 检测治疗前循环TTMV HPV DNA,覆盖5种基因型(16、18、31、33和35),采用市售基于微滴式数字聚合酶链反应的检测方法。
  • 结果按可检出/不可检出或连续评分(片段/mL)分析。

主要发现

  • 110例患者中96例为男性(87%),104例为白人(95%),平均(SD)年龄62.2(9.4)岁。
  • 98例(89%)可检出循环TTMV HPV DNA,中位(IQR)评分315(47-2686)片段/mL(范围0-60061片段/mL)。
  • 可检出TTMV HPV DNA者中86例(88%)为基因型16,12例(12%)为其他基因型。
  • 临床N0期患者中仅4/11(36%)可检出DNA,临床N1-N3期患者中94/99(95%)可检出(比例差59%,95%CI 30%-87%)。
  • 不可检出TTMV HPV DNA的患者中超过半数(7/12[58%])为临床N0期。

局限性

  • 原文结论指出该关联的机制有待进一步研究。
  • 原文结论指出该生物标志物用于基线不可检出患者监测的价值有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Circulating tumor tissue-modified viral (TTMV) human papillomavirus (HPV) DNA is a dynamic, clinically relevant biomarker for HPV-positive oropharyngeal squamous cell carcinoma. Reasons for its wide pretreatment interpatient variability are not well understood. OBJECTIVE: To characterize clinicopathologic factors associated with TTMV HPV DNA. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included patients evaluated for HPV-positive oropharyngeal squamous cell carcinoma at Dana-Farber Cancer Institute in Boston, Massachusetts, between December 2019 and January 2022 and who were undergoing curative-intent treatment. EXPOSURES: Clinicopathologic characteristics including demographic variables, tumor and nodal staging, HPV genotype, and imaging findings. MAIN OUTCOMES AND MEASURES: Pretreatment circulating TTMV HPV DNA from 5 genotypes (16, 18, 31, 33, and 35) assessed using a commercially available digital droplet polymerase chain reaction-based assay, considered as either detectable/undetectable or a continuous score (fragments/mL). RESULTS: Among 110 included patients, 96 were men (87%) and 104 were White (95%), with a mean (SD) age of 62.2 (9.4) years. Circulating TTMV HPV DNA was detected in 98 patients (89%), with a median (IQR) score of 315 (47-2686) fragments/mL (range, 0-60 061 fragments/mL). Most detectable TTMV HPV DNA was genotype 16 (n = 86 [88%]), while 12 patients (12%) harbored other genotypes. Circulating TTMV HPV DNA detection was most strongly associated with clinical N stage. Although few patients had clinical stage N0 disease, only 4 of these 11 patients (36%) had detectable DNA compared with 94 of 99 patients (95%) with clinical stage N1 to N3 disease (proportion difference, 59%; 95% CI, 30%-87%). Among patients with undetectable TTMV HPV DNA, more than half (7 of 12 [58%]) had clinical stage N0 disease. The TTMV HPV DNA prevalence and score increased with progressively higher clinical nodal stage, diameter of largest lymph node, and higher nodal maximum standardized uptake value on positron emission tomography/computed tomography. In multivariable analysis, clinical nodal stage and nodal maximum standardized uptake value were each strongly associated with TTMV HPV DNA score. Among 27 surgically treated patients, more patients with than without lymphovascular invasion had detectable TTMV HPV DNA (12 of 12 [100%] vs 9 of 15 [60%]). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, circulating TTMV HPV DNA was statistically significantly associated with nodal disease at HPV-positive OPSCC diagnosis. The few patients with undetectable levels had predominantly clinical stage N0 disease, suggesting assay sensitivity for diagnostic purposes may be lower among patients without cervical lymphadenopathy. Mechanisms underlying this association, and the use of this biomarker for surveillance of patients with undetectable baseline values, warrant further investigation.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Rettig EM, Wang AA, Tran NA, et al. Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36301568. doi:10.1001/jamaoto.2022.3282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。